Opportunity for Investors: Join the Securities Fraud Lawsuit Against Aquestive Therapeutics

An Investor's Call to Action: Securities Fraud Lawsuit Against Aquestive Therapeutics

In a significant development for investors of Aquestive Therapeutics, Inc., a class action lawsuit opportunistic call has been made following allegations of misleading statements made about the company. The Rosen Law Firm has reached out to purchasers of Aquestive securities that were acquired between June 16, 2025, and January 8, 2026. If you are one of these investors, your ability to secure compensation could be just around the corner.

Understanding the Class Period

The class period is crucial in determining eligibility for participation in the lawsuit. It covers the time frame from June 16, 2025, to January 8, 2026. During this period, investors who purchased securities from Aquestive are urged to come forward, as they may be entitled to recovery without being liable for out-of-pocket fees. This contingency fee arrangement means that you can seek compensation with minimal financial risk.

What Claims Are Being Made?

Allegations have surfaced suggesting that the defendants purportedly involved made false or misleading statements concerning the status of Aquestive's New Drug Application (NDA) for their product Anaphylm. The lawsuit emphasizes that critical information—primarily concerning the human factors impacting the packaging and administration of the sublingual film—was concealed or downplayed, leading to potential damages for the investors as this information came to light.

When the truth about the product's state and associated risk was revealed, market reactions suggested that investors suffered financial losses. It is paramount that those affected act swiftly to secure their rights under the law.

Steps to Join the Lawsuit

If you bought shares of Aquestive during the relevant class period, joining this class action may be your next step. You have several options to seek more information or express your intention to participate:

- Visit Rosen Legal’s submission form
- Call Phillip Kim, Esq. toll-free at 866-767-3653
- Email inquiries can be sent to [email protected]

For those interested in taking a more active role, there is a chance to serve as the lead plaintiff in this class action lawsuit. However, it’s critical to note that applications for lead plaintiff must be submitted no later than May 4, 2026. A lead plaintiff is essential, as they play a pivotal role in guiding the litigation on behalf of other class members.

Choosing the Right Legal Counsel

The Rosen Law Firm highlights the importance of selecting qualified legal representation when navigating securities class actions. The firm possesses a stellar track record, striving for significant outcomes in previous litigation. Notably, they have handled some major cases and have been recognized for their performance in securities class action settlements. Investors are encouraged to choose counsel with such a prominent background rather than firms that may not directly litigate cases but merely refer clients.

Why This Case Matters

This lawsuit isn’t just about seeking compensation; it symbolizes a collective effort by investors to hold corporations accountable for their disclosures. The details regarding Aquestive’s NDA and how that impacts investors underline the importance of transparency from public companies. As the market witnessed fluctuations following the misinformation, it becomes evident why shareholders are pushing back through legal means.

In conclusion, if you invested in Aquestive Therapeutics, Inc. during the aforementioned period, now is the time to consider your options. Whether it’s joining the lawsuit or speaking with legal representatives, taking informed action can potentially recover losses and contribute to greater corporate accountability. Don’t miss this chance; take the steps necessary to protect your investment today.